Treatment With Intravitreal Avastin for Large Uveal Melanomas

Memorial Sloan Kettering Cancer Center (MSK)

Status

Completed

Conditions

Uveal Melanoma

Treatments

Drug: AVASTIN

Study type

Interventional

Funder types

Other

Identifiers

NCT00596362

07-040

Details and patient eligibility

About

The purpose of this study is to test the safety and effectiveness of Avastin introduced into the inside of the eyeball in causing shrinkage of the uveal melanoma (tumor of the eye). Avastin is an anti-cancer drug specially designed to shrink blood vessels within tumors.

Enrollment

1 patient

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients diagnosed with large uveal melanomas who elect to undergo enucleation.
Patients diagnosed with uveal melanomas with tumor thickness > 10 mm or basal diameter > 16 mm, as measured by ultrasound examination, funduscopic examination, or transillumination.

Exclusion criteria

Cases that do not meet the above criteria for tumor size will be ineligible to participate in the study.
Patients with history of metastatic cancer (other than melanoma).
Patients not able to provide consent for the study.
Patients with clinical or radiographic evidence of extraocular extension of the tumor.
Patients with a previous history of an adverse reaction to intravitreal injection.
Patients with a poor view of the fundus due to cataract or vitreous hemorrhage.
Patients with intravitreal silicone oil or gas tamponade.
Patients < 18 years of age.
Women known to be pregnant.